Avivagen Patent Applications Allowed in Indonesia and Mexico
April 05 2013 - 8:00AM
Access Wire
OTTAWA, ONTARIO, April 4, 2013 - Avivagen Inc. (TSXV: VIV), a
wellness company committed to developing products that support the
health of animals and the people who care for them, is pleased to
announce that its patent application "Compositions and methods for
promoting weight gain and feed conversion" has been Allowed by the
Patent Offices of Indonesia and Mexico.
The Allowances relate to claims for oxidized carotenoids,
including OxC-beta, as non-antibiotic alternatives in commercial
animal feeds - for species such as cattle, poultry, sheep, swine,
crustaceans and fish. Indonesia is the world's eighth largest
producer of chicken eggs and chicken meat, and it is a significant
contributor to world tilapia and shrimp output. In turn, Mexico is
the world's fourth largest producer of chicken eggs and meat, and
the fourth largest pork producer in the Americas, after the U.S.,
Brazil and Canada.
Avivagen has identified its technology as a non-antibiotic
alternative for promoting growth and efficient feed conversion in
food-animals. In many countries, the majority of antibiotics are
used in animal feeds for such non-therapeutic purposes. As asserted
by the Ontario Medical Association on March 20, 2013, there is
growing concern that this high-volume use of antibiotics in animals
promotes the development of the antibiotic-resistant microorganisms
that are a threat to human health.
In response to this situation, there is increasing pressure to
restrict the use of antibiotics in animal feed and an un-met need
for safe and effective non-antibiotic agents for use in
food-animals. Because feed is a large production cost, a
non-antibiotic product that can improve feed conversion and enhance
growth is of potential value to producers.
Similar claims have been allowed or granted for this patent
family in Canada, the United States, Australia, Russia and South
Africa. The feeding claims are pending in other jurisdictions,
including Europe, Asia and South America. Other patent families
provide further protections to Avivagen's technologies.
About Avivagen
Avivagen Inc. is a publicly-listed life sciences company trading
on the TSX Venture Exchange under the ticker "VIV." The Company's
goal is to develop and deliver scientifically-proven solutions that
can truly benefit companion and food animals by taking advantage of
natural mechanisms for maintaining optimal health. Avivagen's
targeted markets include Pet Wellness and Livestock
Productivity.
The company has sites located in partnership facilities of the
National Research Council of Canada (NRC) - In Ottawa (Chemistry)
and Charlottetown, Prince Edward Island (Nutriscience).
More information can be found at www.avivagen.com.
About OxC-Beta
Avivagen's proprietary and patent-protected technology enhances
the body's own systems to maintain and improve health, particularly
by supporting immune function. Avivagen's commercial technology is
Fully-Oxidized Beta-Carotene (OxC-beta).
OxC-Beta compounds occur naturally in vegetation but in minute
amounts. They have been developed to support the health of
companion animals and for use in the global food animal market.
Research results indicate OxC-Beta helps support immune
function, which can result in meaningful overall health
improvements. In pets, improvements are seen in overall vitality
and energy, skin, coat and gastrointestinal wellness. Food Animal
benefits include healthier growth, better utilization of feed and
decreased mortality.
Forward Looking Statements
This news release includes certain forward-looking statements
that are based upon current expectations, which involve risks and
uncertainties associated with the business of Avivagen Inc. and the
environment in which the business operates. Any statements
contained herein that are not statements of historical facts may be
deemed to be forward-looking, including those identified by the
expressions "will", "anticipate", "believe", "plan", "estimate",
"expect", "intend", and similar expressions. The forward-looking
statements reflect the current expectations of Avivagen Inc.
regarding future results or events. These forward-looking
statements are subject to a number of risks and uncertainties that
could cause actual results or events to differ materially from
current expectations. Avivagen assumes no obligation to update the
forward-looking statements, or to update the reasons why actual
results could differ from those reflected in the forward-looking
statements. The results of treatment described above are based on
historical results. Different animals may experience different
results from the treatments described above.
Neither TSX Venture Exchange nor its Regulation Services
Provider (as that term is defined in the policies of the TSX
Venture Exchange) accepts responsibility for the adequacy or
accuracy of this release.
For more information:
Cameron Groome
CEO and President, Avivagen Inc.
Phone: 613-949-8164
c.groome@avivagen.com
Avivagen (TSXV:VIV)
Historical Stock Chart
From Jul 2024 to Aug 2024
Avivagen (TSXV:VIV)
Historical Stock Chart
From Aug 2023 to Aug 2024